Greenpanel Industries shares drop 2% as Q4 revenue falls 5.6% YoY to Rs 374.5 crore, EBITDA down 6.9% YoY
Shares of Greenpanel Industries fell over 2% during morning trade on Friday after the company announced its financial results for the fourth quarter of FY25. The report reflected a year-on-year decline across key performance indicators. As of 9:34 AM, the shares were trading 2.51% lower at Rs 245.30.
Revenue for the quarter stood at ₹374.5 crore, a decrease of 5.6% compared to ₹396.5 crore in the same quarter last year. EBITDA declined by 6.9% to ₹47.9 crore, down from ₹51.5 crore a year ago. The EBITDA margin was reported at 12.8%, slightly lower than the 13% margin recorded in the corresponding quarter last year.
Net profit for the quarter was ₹29.4 crore, representing a decline of 1.4% from ₹29.8 crore in Q4 FY24.
Greenpanel Industries shares opened at ₹250.30, touched a high of ₹251.60 and a low of ₹240.82 during the session. The stock remains well below its 52-week high of ₹427.00 but is trading above its 52-week low of ₹202.81.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
7 hours ago
- Business Upturn
Nibe signs Technical Collaboration Agreement with Israel's Elbit Systems for PULS rocket system
Nibe Limited has officially entered into a technical collaboration agreement with Israel-based defence technology firm Elbit Systems Land Limited. Signed on July 26, 2025, the agreement focuses on the transfer of license and technology for the Precise & Universal Launch System (PULS), a high-range artillery rocket system. Under this agreement, Elbit will provide Nibe with the necessary know-how and licensing rights to manufacture and assemble the PULS system in India. The system is designed for long-range precision targeting, capable of engaging threats at distances up to 300 kilometers. The collaboration aims to establish a local manufacturing setup for PULS in India, allowing Nibe to take on responsibilities for development, assembly, and integration. The financial terms of the agreement are expected to be finalized within 45 days from the signing date. This is a purely international partnership between two independent entities, with no related party transaction involved. Neither Nibe's promoter group nor its affiliates have any stake or interest in Elbit Systems Land Limited. The agreement aligns with the regulatory requirements under SEBI's disclosure norms. With this development, Nibe Limited expands its presence in the defence manufacturing sector by bringing advanced rocket system capabilities to the domestic market through technology collaboration with a global player. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
9 hours ago
- Business Upturn
Kotak Mahindra Bank Q1 results: Net profit down 47% YoY to Rs 3,282 crore, GNPA at 1.48% vs 1.39% QoQ
Kotak Mahindra Bank reported a 47.5% year-on-year (YoY) decline in net profit for the quarter ended June 30, 2025, with Q1 FY26 profit standing at Rs 3,281.68 crore compared to Rs 6,249.82 crore in Q1 FY25. The sharp fall is primarily due to the absence of exceptional gains booked in the same quarter last year. Net Interest Income (NII) grew 6% YoY to Rs 7,259 crore from Rs 6,843 crore, reflecting steady growth in lending and core banking operations. Total income rose to Rs 16,916 crore from Rs 15,675 crore YoY. Operating profit (before provisions) rose to Rs 5,563.69 crore from Rs 5,254.11 crore in the previous year. Provisions and contingencies, however, jumped to Rs 1,207.76 crore from Rs 578.48 crore YoY, impacting the bank's profitability. Asset quality weakened slightly: Gross NPA: Rs 6,637.70 crore (1.48%) vs Rs 5,477.15 crore (1.39%) QoQ Net NPA: Rs 1,530.93 crore (0.34%) vs Rs 1,376.33 crore (0.35%) QoQ Despite steady growth in core income, the YoY profit decline was driven by the high base effect of last year's Rs 3,519.90 crore exceptional gain. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
Business Upturn
10 hours ago
- Business Upturn
Alembic Pharma gets USFDA nod for Carbamazepine Extended-Release Tablets
Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Carbamazepine Extended-Release Tablets USP in strengths of 100 mg, 200 mg, and 400 mg. These tablets are the generic version of Tegretol-XR, a widely used anticonvulsant drug developed by Novartis Pharmaceuticals. Alembic's version is therapeutically equivalent to the original, meaning it meets the same standards for quality, strength, and effectiveness. Carbamazepine Extended-Release Tablets are primarily used to treat seizure disorders and are also prescribed for trigeminal neuralgia, a chronic pain condition affecting the facial nerves. According to IQVIA data, the US market for this drug was valued at approximately $71 million for the 12-month period ending March 2025. With this approval, Alembic now has a total of 225 ANDA approvals from the USFDA, which includes 202 final approvals and 23 tentative approvals. About Alembic Pharmaceuticals Founded in 1907 and headquartered in India, Alembic Pharmaceuticals is a vertically integrated pharmaceutical company known for its strong focus on research and development. It manufactures and markets generic drugs across global markets, with several of its facilities approved by top regulatory bodies including the USFDA. In India, Alembic is a leader in branded generics, with a product portfolio promoted by a field force of over 5,500 professionals. Its products are widely recognized and trusted by healthcare professionals and patients alike. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
